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Background—Angioplasty stimulates proliferation and migration of vascular smooth muscle cells (VSMC), leading to
neointimal thickening and vascular restenosis. In a rat model of balloon catheter injury (BCI), we investigated whether
alterations in expression of Ca2-activated K channels (KCa) contribute to intimal hyperplasia and vascular restenosis.
Methods and Results—Function and expression of KCa in mature medial and neointimal VSMC were characterized in situ
by combined single-cell RT-PCR and patch-clamp analysis. Mature medial VSMC exclusively expressed large-
conductance KCa (BKCa) channels. Two weeks after BCI, expression of BKCa was significantly reduced in neointimal
VSMC, whereas expression of intermediate-conductance KCa (IKCa1) channels was upregulated. In the aortic VSMC
cell line, A7r5 epidermal growth factor (EGF) induced IKCa1 upregulation and EGF-stimulated proliferation was
suppressed by the selective IKCa1 blocker TRAM-34. Daily in vivo administration of TRAM-34 to rats significantly
reduced intimal hyperplasia by40% at 1, 2, and 6 weeks after BCI. Two weeks of treatment with the related compound
clotrimazole was equally effective. Reduction of intimal hyperplasia was accompanied by decreased neointimal cell
content, with no change in the rate of apoptosis or collagen content.
Conclusions—The switch toward IKCa1 expression may promote excessive neointimal VSMC proliferation. Blockade of
IKCa1 could therefore represent a new therapeutic strategy to prevent restenosis after angioplasty. (Circulation. 2003;
108:1119-1125.)
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Percutaneous balloon angioplasty, an intervention to relievearterial stenosis and improve blood flow, is complicated by
vascular restenosis within weeks as the result of proliferation of
vascular smooth muscle cells (VSMC) and consequent renar-
rowing of the vessel lumen.1 Complex interactions between
numerous growth-stimulating molecules have been proposed to
promote migration and proliferation of VSMC,2 leading to
neointima formation. Proliferating VSMC are characterized by
alterations in functional plasticity as they switch from a contrac-
tile phenotype to a dedifferentiated phenotype.
Ca2-activated K channels (KCa) are important regulators of
VSMC function.3,4 Mature VSMC predominantly express the
calcium-activated large-conductance channel (BKCa or maxi K),4 a
product of the Slo gene,5 which plays a pivotal role in VSMC
relaxation by dampening depolarization-dependent activation of
Ca2 channels and Ca2 influx through membrane hyperpolariza-
tion.3,4 In contrast to the vasodilatory function of BKCa, the role of
other KCa channels in VSMC is incompletely understood. The
intermediate-conductance KCa channel encoded by the IKCa1 gene
(also known as IK1, hSK4, KCa4, and KCa3.1 as per the new
IUPHAR nomenclature: http://www.iuphar.org/compendium2.
htm) has been proposed to be an important regulator of cell
proliferation. In lymphocytes and fibroblasts, upregulation of IKCa1
expression is an essential step in mitogenesis.6–8
In the present study, we tested the hypothesis that a
reorganization of KCa channel expression pattern after
angioplasty promotes neointimal cell proliferation. After
balloon catheter injury (BCI) to rat carotid artery (CA),
neointimal VSMC switched KCa gene expression from Slo
to IKCa1, representing a change from a KCa subtype
mediating vasodilation to a KCa subtype promoting cell
proliferation. Blockade of IKCa1 by the antimycotic clo-
trimazole (CLT) and its selective derivative TRAM-346
resulted in inhibition of epidermal growth factor (EGF)-
stimulated VSMC proliferation in vitro and in reduced
neointima formation in vivo.
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Methods
Balloon Catheter Injury and Treatment Protocols
Under the aegis of a protocol approved by the local Animal Care and
Use Committee, Sprague-Dawley rats (weight, 350 to 450 g) were
subjected to BCI of the left CA by use of a 2F Fogarty embolectomy
catheter (Baxter Scientific).9 Rats were killed 2 weeks (n5) after
BCI, and left and right CA were excised. Separate groups (each n4
to 11) were treated with daily subcutaneous injections of TRAM-34
(1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole; 120 mg/kg per
day) or the vehicle (peanut oil) for 1, 2, and 6 weeks after BCI.
Another group (n7) was treated with CLT (120 mg/kg per day) for
2 weeks. TRAM-34 and CLT serum levels and TRAM-34 concen-
trations in liver and subcutaneous fat were quantitatively determined
by bioassay.10
Neointimal thickening was determined in paraffin-embedded and
differential nonserial cross sections stained with hematoxylin and
eosin to visualize nuclei and cytoplasm, or with Sirius red to detect
collagen. Histomorphological analysis was done with the use of a
computerized analysis system (Scion Image) in a blinded manner.
Mature and Neointimal VSMC and Patch-Clamp
Experiments
Isolation of mature and neointimal VSMC, whole-cell patch-clamp
experiments in situ, and data analysis were performed as described
previously.11–13
Reverse Transcription and Single-Cell RT-PCR
Reverse transcription of mRNA from single-cell samples and “mul-
tiplex” single-cell RT-PCR were performed as described previous-
ly.11,12 Primer pairs for small KCa (rSK1–3), rIKCa1, and endothelial
nitric oxide synthase (reNOS) as endothelial cell markers are stated
elsewhere.12 First and “nested” primer pairs for rSlo and myosin
heavy chain (rMyHC) as VSMC markers spanned intronic se-
quences, and identity of PCR products was verified by sequencing:
Primer, rSlo: F5-GGACTTAGGGGATGGTGGTT-3; R5-
GGGATGGAGTGGACAGAGGA-3; nested:F5-TTTACCGGCT-
G AGAGATGCC-3; R5-TGTGAGGAGTGGGAGGAATGA-3;
(GenBank accession:-AF135265) rMyHC: F5-CATCAATGCCAA-
CCGCAG-3; R5-TCCCGAGCATCCATTTCTTC-3; nested: F5-
AGGCCACTGAGAGCAATGAG-3; R5-TCAATAACTCTACG-
GCCTCCA-3. (GenBank accession:-X16262).
Detection of Apoptosis
Apoptotic nuclei in the neointima were detected by TUNEL method
(Apoptaq-Plus; Qbiogene). Slices were counterstained with methyl
green.
In Vitro Proliferation Studies
To induce growth arrest, rat aortic VSMC (cell line: -A7r5) were
kept in serum-free medium for 48 hours before stimulation with EGF
(20 ng/mL) in the presence or absence of TRAM-34, CLT, TRAM-7
(1-tritylpyrrolidine), or IbTX. At 5% to 10% confluence, photomi-
crographs of cells were taken in fixed fields before and 48 hours after
stimulation, and the percent increase in cell count was calculated.
RNA Isolation and Quantitative Real-Time RT-PCR
Cells were harvested at 2 hours or 48 hours after stimulation by
scraping. RNA was isolated with TRIZOL and was reverse-
transcribed with M-MLV reverse transcriptase (both Life Technol-
ogies). Expression was quantified with an ABI-Prism-7700 Se-
quence Detection System (Perkin-Elmer ABI), using intron-spanning
primers and internal oligonucleotides labeled with 6-carboxy-fluo-
rescein on the 5end and 6-carboxytetramethylrhodamine on the
3end. Identity of PCR products was verified by sequencing. Lin-
earity of each PCR assay was confirmed by serial dilutions of cDNA;
primer and internal oligonucleotides: rIKCa1: F5-CTGAGAGG-
CAGGCTGTCAATG-3; R5-ACGTGTTTCTCCGCCTTGTT-3;
P5-AAGATTGTCTGCTTGTGCACCGGAGTC-3; rMyHC: F5-
CATCAATGCCAACCGCAG-3; R5-TCCCGAGCATCCATTT-
CTTC-3; P5-TGAGGCCATGGGCCGTGAGG -3; rat glyceralde-
hyde-3-phosphate dehydrogenase (rGAPDH): F5-CGGCACAGT-
CAAGGCTGAG-3; R5-CAGCATCACCCCATTTGATGT-3;
P5-CCCATCACCATCTTCCAGGAGCGA-3 (GenBank acces-
sion: -AB017801).
Each 25-L PCR reaction consisted of 500 nmol forward and
reverse primer, 150 nmol probe, 3 L cDNA, and 1TaqMan
Universal Master Mix (Perkin-Elmer ABI). PCR parameters were
50°C2 minutes, 95°C10 minutes, and 50 cycles at 95°C15
seconds, 60°C1 minute.
Threshold cycles (Ct) were calculated by means of TaqMan
software (ABI, User Bulletin No. 2). Real-time RT-PCR signals for
rIKCa1 and rMyHC were standardized to rGAPDH by use of the
equation CtXCtrGAPDHCt. The equation, Ctw/oCtXCt,
was used to determine changes in expression, where the CtXvalue
(EGF-stimulated) was subtracted from the control Ctw/ovalue
(w/owithout stimulus) of the same experiment. Fold increases in
expression were calculated by the equation 2Ctfold change.
Statistical Analysis
Data are given as meanSEM. If appropriate, the Wilcoxon rank
sum test or 2 analyses were used to assess differences between
groups. Values of P	0.05 were considered significant.
Results
Alterations in KCa Functional Expression in
Neointimal VSMC After BCI
To measure functional KCa channel expression, we performed
whole-cell patch-clamp experiments on freshly isolated ma-
ture VSMC and neointimal VSMC in situ after BCI.12,13
Mature VSMC (n14) from normal CA exhibited an outward
Ca2 activated and voltage-dependent K current with char-
acteristics of the cloned BKCa channel.4,5,13 The outward K
current was small at negative membrane potentials, increased
steeply at positive membrane potentials, and was blocked by
the selective BKCa inhibitor iberiotoxin (IbTX) (Figure 1A,
left panel), with a potency (KD 113 nmol/L, Figure 1A, left
inset) similar to the cloned BKCa channel. The selective SKCa
blocker apamin (APA, 1 mol/L), and the IKCa blockers
TRAM-34 (1 mol/L) and CLT (1 mol/L)6,7,14 had no effect
on this current (data not shown). A small residual voltage-
gated Ca2-independent (KV) K current (1.10.2 pA/pF at 0
mV) was sensitive to 2 mmol/L 4-aminopyridine (Figure 1A,
right panel). The voltage dependence of the composite BKCa
plus Kv current in mature VSMC, normalized for cell capac-
itance (IK [pA/pF]), is shown in Figure 1D.
Two weeks after BCI, neointimal VSMC (n30) had a
substantially altered K current pattern. The majority of
neointimal VSMC (19/30) expressed two KCa currents (Figure
1B, left panel) with properties resembling BKCa and IKCa
channels. The IKCa component seen at negative potentials was
eliminated by the selective IKCa inhibitor TRAM-34, leaving
a residual BKCa current that could be suppressed by IbTX
(Figure 1B, left panel). BKCa currents were absent in 11 of 30
neointimal VSMC that contained only IKCa currents (Figure
1B, right panel, and Figure 1C) with properties similar to the
cloned and native IKCa channels.6–8,11,12,14–16,18 These IKCa
currents were blocked by TRAM-34 in a dose-dependent
fashion, 500 nmol/L TRAM-34 completely abolishing the
current (Figure 1B, right panel). The dose-response curves in
Figure 1C demonstrate that charybdotoxin (ChTX; KD 51
nmol/L), TRAM-34 (KD 102 nmol/L), and CLT (KD 314
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nmol/L) blocked these currents with potencies similar to the
cloned IKCa1 channel.6,14,18 The currents were not affected
by TRAM-7 (1 mol/L), an inactive analog of TRAM-34, or
by the SK blocker APA (1 mol/L) or the Kv blocker
4-aminopyridine (2 mmol/L) (not shown). When normalized
for membrane capacitance (Figure 1D), the mean K current
in neointimal VSMC was significantly increased at 40 and
0 mV and reduced at 100 mV, compared with mature
VSMC, reflecting the shift from BKCa expression in mature
VSMC to a mixture of IKCa and BKCa in neointimal cells.
Alterations in BKCa and IKCa1 mRNA
Expression in Neointimal VSMC After BCI
Correlate With Changes in Functional Expression
We used “multiplex” single-cell RT-PCR to determine
whether the changes in functional BKCa and IKCa expression
after BCI correlated with alterations in mRNA levels for the
Slo and IKCa1 genes, respectively. The VSMC marker
MyHC was detected in all mature VSMC (34/34) and in all
neointimal VSMC (18/18) 2 weeks after BCI. Endothelial
cell–specific eNOS expression was not detected in any of the
cell samples, demonstrating that our VSMC samples are not
contaminated with endothelial cells. None of the negative
controls (n24) yielded any PCR products.
Mature VSMC that functionally express BKCa and not IKCa
channels (Figure 1A) contained substantial quantities of Slo
mRNA (87%; 54/62) and no IKCa1 mRNA (0/27; Figure 2).
Two weeks after BCI, the KCa gene expression pattern in
neointimal VSMC was altered (Figure 2), in keeping with the
changes observed in the amplitude of BKCa and IKCa currents
in these cells (Figure 1B and 1D). Slo transcripts were
detected less frequently (24/67; 36%) and IKCa1 tran-
scripts more frequently (42/67;63%) than in mature VSMC
(2 analysis; P	0.01 and P	0.001, respectively). Transcripts
of SK1-SK3 genes were not detected in mature or neointimal
VSMC (data not shown). These results indicate that changes
in Slo and IKCa1 mRNA levels after BCI contribute to the
changes in BKCa and IKCa functional expression in VSMC.
EGF-Induced Upregulation of IKCa1 Expression
and Proliferation of VSMC
The switch from BKCa expression in mature VSMC to a
mixture of IKCa and BKCa in neointimal cells after BCI may
reflect a change from a contractile to a proliferating pheno-
type. To test this hypothesis, we examined IKCa function and
IKCa1 mRNA expression in the aortic VSMC cell line A7r5
after mitogenic stimulation with EGF. Forty-eight hours after
stimulation, the amplitude of the K current increased 3-fold
Figure 1. Mature VSMC express BKCa
currents; neointimal VSMC express IKCa
currents at week 2 after BCI. A, Left
panel, BKCa currents in mature VSMC
and channel blockade by 100 nmol/L
IbTX. Inset, Concentration-dependent
blockade of BKCa currents by IbTX (n4
to 5). Right panel, Voltage-gated K cur-
rents in mature VSMC recorded with a
Ca2-free pipette solution and blockade
by 4-AP. B, Left panel, Mixed BKCa and
IKCa currents in neointimal VSMC at
week 2 after BCI and blockade of IKCa
currents by TRAM-34 and BKCa currents
by IbTX. Right panel, Concentration-
dependent blockade of IKCa currents by
TRAM-34 in a cell expression pure IKCa1
current. C, Pharmacology of IKCa cur-
rents; TRAM-34 (n6 to 7, ), CLT (n3
to 5; ), and ChTX (n3 to 4; ). D,
Quantitative analysis of IKCa and BKCa
currents in mature VSMC () and neointi-
mal VSMC (). *P	0.05,**P	0.01, Wil-
coxon rank sum test.
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compared with untreated cells (Figure 3A and Table 1,
P	0.01). Parallel RT-PCR studies revealed a 6-fold increase
in IKCa1 mRNA levels as early as 2 hours after EGF
stimulation and a 3-fold increase after 48 hours (Table 1).
Pharmacological studies confirmed that the K currents in
EGF-treated cells were indeed IKCa1 (Figure 3B). The
currents were not affected by the BKCa inhibitor IbTX (100
nmol/L) but were blocked by TRAM-34 (KD 81 nmol/L),
ChTX (KD 61 nmol/L), and CLT (KD 301 nmol/L) with
potencies similar to IKCa1. Thus, the channel expression
pattern in EGF-stimulated A7r5 cells resembles that seen in
proliferating neointima in vivo.
To test whether the enhanced IKCa expression in VSMC
might have functional consequences, we examined whether
the IKCa1 inhibitors TRAM-34 and CLT could suppress
EGF-stimulated mitogenesis of A7r5 cells. The cell count
increased 1458% 48 hours after EGF stimulation but only
1093% in unstimulated A7r5 cells (P	0.001). TRAM-34
(IC50 84 nmol/L) and CLT (IC50 145 nmol/L) suppressed
EGF-stimulated proliferation in a dose-dependent fashion,
reducing mitogenesis to baseline levels at 100 nmol/L (Figure
3C). The inactive triarylmethane TRAM-7 (1 mol/L) did not
suppress proliferation, indicating that the suppressive effect
of TRAM-34 and CLT are not the result of nonspecific
toxicity. The BKCa blocker IbTX (100 nmol/L) also had not
effect on proliferation (Figure 3C). These results suggest that
upregulation of IKCa channel expression is required for
EGF-induced VSMC proliferation, as has been reported in
lymphocyte activation and fibroblast mitogenesis.6–8,18
TRAM-34 and CLT Suppress BCI-Induced
Intimal Hyperplasia In Vivo
IKCa upregulation in proliferating neointimal VSMC and the
effectiveness of IKCa blockers in suppressing EGF-induced
proliferation of A7r5 VSMC suggest that in vivo IKCa
blockade might reduce intimal hyperplasia in CA of rats after
BCI. We tested this idea by administration of CLT and
TRAM-34 after BCI. Data from these experiments are sum-
marized in Table 2, and representative cross sections of CA
are shown in Figure 4.
An initial 2-week trial with CLT (120 mg/kg per day)
yielded encouraging results, but the CLT-treated rats gained
less weight than the vehicle-treated group, and hepatomegaly
developed as the result of reported CLT liver toxicity medi-
ated by inhibition of P450-dependent enzymes. We therefore
switched to the selective IKCa inhibitor TRAM-34 (120 mg/kg
Figure 2. Multiplex single-cell RT-PCR analysis of single mature
and VSMC. Ethidium bromide–stained gels of RT-PCR products
from representative mature VSMC and neointimal VSMC at
week 2 after BCI. rSlo and rIKCa1 (upper panel) and myosin
heavy chain rMyHC (lower panel). Columns show quantitative
analysis of rSlo and rIKCa1 expression in mature VSMC (rats,
n9) and neointimal VSMC (rats, n5). **P	0.01, Wilcoxon rank
sum test.
Figure 3. EGF upregulates IKCa1 expression and induces prolif-
eration of the VSMC line, A7r5. A, Representative Ca2-acti-
vated K currents in unstimulated (w/o) and EGF-stimulated
cells (48 hours). B, Blockade of IKCa currents in A7r5 cells by
100 nmol/L TRAM-34 but not by 100 nmol/L IbTX. C, Dose-
dependent inhibition of EGF-induced proliferation (percent cell
proliferation after 48 hours) by TRAM-34 (n4 to 10, ) and CLT
(n6 to 8, ) but not by inactive TRAM-7 (1 mol/L; n3, ‘) or
by IbTX (100 nmol/L; n7; ). Dashed line indicates baseline
proliferation in A7r5 cells in the absence of EGF.
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per day), which has no effect on P450-dependent enzymes
and does not cause overt acute toxicity after intravenous
administration.6 Although neointima formation progressively
increased from week 1 to week 6 after BCI in the vehicle-
treated group, the area of the neointimal cell layer in the
TRAM-34–treated group was significantly smaller at week 1
(64%; P	0.01), week 2 (35%; P	0.01), and week 6
(43%; P	0.01) after BCI (Figure 4 and Table 2). Two
weeks’ treatment with CLT also resulted in a pronounced
reduction of neointimal formation (50%; P	0.001, Figure
4 and Table 2). The area of the medial smooth muscle cell
layer was not different between rats treated with TRAM-34,
CLT, or vehicle. The ratio of neointimal/medial areas (N/M)
and the wall area bounded by the external elastic lamina
(EEL) in TRAM-34–treated and CLT-treated rats were there-
fore significantly smaller than that of the respective vehicle-
treated groups at all times measured after BCI. Reduced
neointima formation in TRAM-34–treated animals resulted
in larger residual lumina at week 2 (34%; P	0.05) and at
week 6 (44%; P	0.01) after BCI compared with vehicle-
treated rats. CLT-treated animals also displayed larger resid-
ual lumina at 2 weeks (49%; P	0.001) after BCI. When the
lumen area of the injured CA (rL) was normalized to that of
the uninjured contralateral CA (rL/cL), TRAM-34–treated
rats displayed reduced lumen narrowing (higher rL/CL val-
ues) at week 2 (9%; P	0.01) and week 6 (19%; P	0.01)
than vehicle-treated control animals (36% at week 2 and
50% week 6). Less lumen narrowing was also observed in
CLT-treated animals 2 weeks after BCI (18%; P	0.05).
TRAM-34 treatment caused no visible side effects or
macroscopic organ damage during the course of the study.
After transient weight loss in the first week as the result of
surgery, TRAM-34–treated rats gained weight (305 g at
week 2; 996 g at week 6), similar to the vehicle-treated
group (254 g at week 2, 9015 g at week 6). In contrast,
the CLT-treated group gained significantly less weight (76
g; P	0.05) within 2 weeks after BCI.
We used a functional bioassay10 to determine the levels of
TRAM-34 and CLT in serum samples obtained at varying
times (1, 2, 4, 6, 8, 12, 24 hours) after injection.
CLT plasma levels peaked 4 hours after administration (2
mol/L) and then progressively decreased over the next 24
hours (6 hours: 1.2 mol/L; 12 hours: 600 nmol/L; 24 hours:
350 nmol/L). TRAM-34 levels in plasma peaked 1 hour after
administration (1 mol/L) and then dropped more rapidly
than CLT (2 hours: 500 nmol/L; 4 and 6 hours: 200 nmol/L;
8 hours: 150 nmol/L; 24 hours: 120 nmol/L, 48 hours: 100
nmol/L). The continued presence of low levels (70 nmol/L) of
TRAM-34 in the plasma 48 hours after injection suggested
that the compound was partitioning into a “deep compart-
ment” from which it was slowly being released back into the
blood. The presence of 5 mol/L TRAM-34 in the liver and
200 nmol/L in the subcutaneous fat at the 48-hour time point
indicates that the highly lipophilic TRAM-34 (logP4.0
TABLE 1. Mitogenic Regulation of rIKCa1 Expression and Function in A7r5 Cells
Cell Treatment n rGAPDH (Ct)
x-Fold Increase
Cell
Treatment
n
(Cells)
IIKCa
(pA/pF)
rIKCa1
(Ct)
rIKCa1
(Ct)
rMyHC
(Ct)
w/o 16 22.60.5 12.40.4 9.20.3 w/o 14 0.80.2
EGF (2-h) 17 22.70.6 9.60.4‡ 2.8 (6-fold) EGF 16 3.40.6†
EGF (48-h) 11 21.70.8 10.80.4† 1.6 (3-fold) 9.00.4
Real-time RT-PCR analysis of rat intermediate-conductance Ca2-activated K channel (rIKCa1) and rat myosin heavy chain
(rMyHC) expression (left) and IKCa currents at 0 mV (right) in rat VSMC cell line A7r5 after EGF stimulation for 48 hours.
CtCtXCtrGAPDH; CtCtw/oCtX; 2Ct indicates fold increase in expression; w/o, no stimulation.
†P	0.01, ‡P	0.001 vs w/o; Wilcoxon rank sum test.
TABLE 2. Effect of TRAM-34 and CLT on Intimal Hyperplasia After BCI
Treatment Group n
Neointimal
Area, mm2
Medial Area,
mm2
Wall Area
Bounded by
EEL, mm2 N/M
Residual Lumen
Area, mm2 rL/cL
Nuclei Count,
Cell No.
Rate of
Apoptosis,
%
Collagen
Content,
%
Vehicle
1 wk 4 0.0110.010 0.0840.005 0.0950.007 0.130.01 0.220.01 0.930.04 15917
2 wk 11 0.0970.006 0.0990.003 0.1950.009 1.050.06 0.160.01 0.640.05 98482 0.90.6 112
6 wk after BCI 5 0.1690.008 0.0910.008 0.2600.011 1.920.22 0.130.01 0.500.02 152579 		1 193
TRAM-1
1 wk 4 0.0040.001* 0.0840.004 0.0880.004 0.050.01† 0.210.02 0.960.05 4716*
2 wk 6 0.0630.005† 0.0950.002 01580.006† 0.660.05† 0.210.02* 0.910.06† 60136† 1.00.6 152
6 wk after BCI 5 0.0960.018† 0.0820.006 0.1790.022† 1.150.18† 0.180.01† 0.810.06† 61297‡ 		1 114
CLT
2 wk after BCI 7 0.0490.010‡ 0.1020.004 0.1510.009† 0.490.10‡ 0.240.02† 0.820.05* 40782‡ 0.60.5 131
EEL indicates external elastic lamina; N/M, ratio of neointimal/medial areas; and rL/cL, ratio of residual/contralateral lumens.
*P	0.05, †P	0.01, ‡P	0.001 vs vehicle, Wilcoxon rank sum test.
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versus 3.5 for CLT) accumulates in these tissues. Thus, after
subcutaneous administration in peanut oil, TRAM-34 was
slowly released into the blood stream, resulting in serum
levels sufficient to suppress proliferation (in vitro: IC50 8
nmol/L) over a 24- to 48-hour period.
To understand the mechanism by which TRAM-34 and
CLT reduced neointima formation, we investigated cell
proliferation, apoptosis, and extracellular matrix (collagen)
content. The neointimal nuclei count, a measure of cell
proliferation, was reduced by 70% (P	0.05) after 1 week,
by 39% (P	0.01) after 2 weeks, and by 61% (P	0.001)
after 6 weeks of TRAM-34 treatment.
A similar reduction (59%, P	0.001) in the neointimal
nuclei count was observed in the CLT-treated group at 2
weeks after BCI. However, the collagen content and the rate
of apoptosis (percentage of apoptotic nuclei) in the neointima
was not different in TRAM-34–treated and CLT-treated rats
compared with vehicle-treated control animals (Table 2 and
Figure 5A and 5B). Taken together, our results demonstrate
that in vivo IKCa blockade reduces neointima formation and
vessel narrowing through inhibition of VSMC proliferation.
Discussion
Using the rat balloon catheter injury model, we demonstrate
that neointimal formation after angioplasty is associated with
a switch in KCa channel expression from exclusive BKCa
expression in mature contractile VSMC to downregulated
BKCa and upregulated IKCa expression in proliferating neoin-
timal VSMC. A similar upregulated IKCa channel expression
pattern was observed in proliferating aortic VSMC A7r5 cells
after stimulation with EGF, and selective IKCa blockade
suppressed A7r5 mitogenesis in vitro, suggesting that IKCa
channels play an important role in VSMC proliferation.
Consistent with this idea, in vivo blockade of IKCa channels
reduced BCI-triggered neointimal formation and vessel re-
narrowing, which suggests a novel therapeutic strategy for the
prevention of restenosis after angioplasty.
Neointimal proliferation and IKCa upregulation after BCI is
mediated by numerous mitogenic factors. Using the aortic
VSMC line A7r5 as a model system, we demonstrated that
mitogenic doses of EGF augment IKCa1 RNA and IKCa
current amplitude. Upregulated IKCa expression has been
similarly reported to contribute to the proliferation of
mitogen-stimulated fibroblasts8 and human T lympho-
cytes.6,7,14,18 Enhanced IKCa1 expression might therefore be
a functional characteristic of proliferating and dedifferenti-
ated cells.8,15
IKCa channels may promote VSMC mitogenesis by enhanc-
ing the electrochemical driving force for Ca2 influx through
membrane hyperpolarization and thus sustain a high intracel-
lular Ca2 concentration required for gene transcription, as
has been reported in lymphocytes and fibroblasts.6,7,18 IKCa1
may play a more important role than BKCa in shaping Ca2
signals of proliferating VSMC because its higher Ca2 affin-
ity3,4,6,7,11,13–16 would result in channel opening and mem-
brane hyperpolarization in response to subtle increases in the
intracellular Ca2 concentration. Induction of IKCa1 expres-
sion might thus be a required step for neointimal VSMC
proliferation after BCI. Consistent with such a role, IKCa1
blockade by CLT and the specific inhibitor TRAM-34 sup-
pressed the proliferation of cultured VSMC. IKCa1 blockers
may therefore have therapeutic value for preventing neointi-
mal proliferation and restenosis after BCI.
Figure 4. TRAM-34 and CLT reduce neointima formation after
BCI. Upper panel, Representative cross sections of carotid
arteries stained with hematoxylin and eosin after treatment with
TRAM-34 or vehicle (Ve) at week 1 after BCI; original magnifica-
tion 200; arrows indicate neointima/media borders. Middle
panel, Representative cross sections after treatment with
TRAM-34, CLT, or Ve at week 2 after BCI; original magnification
50. Lower panel, Representative cross sections after treatment
with TRAM-34, CLT, or Ve at week 6 after BCI.
Figure 5. TRAM-34 and clotrimazole had no effect on collagen
content or rate of apoptosis in the neointima after BCI. A, Rep-
resentative cross sections stained with Sirius red (collagen stain)
after treatment with TRAM-34, CLT, or vehicle (Ve) at week 2
after BCI; original magnification 100. B, Representative cross
sections stained by use of the TUNEL method for detection of
apoptotic nuclei in the neointima after treatment with TRAM-34,
CLT, or Ve at week 2 after BCI; sections were counterstained
with methyl green to visualize all nuclei; original magnification
400; arrows indicate apoptotic nuclei.
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In a rat model of BCI, in vivo administration of CLT
significantly reduced neointimal thickening, but the trial was
discontinued after 2 weeks because of reduced weight gain
and the development of severe hepatomegaly, presumably
because of liver toxicity17 caused by blockade of cytochrome
P450–dependent enzymes.6 A subsequent trial with TRAM-
34, an IKCa1 selective inhibitor that does not block
cytochrome-P450 enzymes or exhibit acute toxicity,6 signif-
icantly reduced neointimal hyperplasia and vessel narrowing
without causing visible signs of organ damage. The therapeu-
tic effect of TRAM-34 was due to inhibition of neointimal
cell proliferation and not due to increased apoptosis or
decreased matrix formation. In conclusion, targeting IKCa1
channels in proliferating VSMC with TRAM-34 might have
therapeutic utility in the prevention of restenosis after angio-
plasty and for the treatment of other cardiovascular disorders
characterized by abnormal VSMC proliferation.
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